Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Appointed COO

Kaleido Biosciences, Inc. (KLDO) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/10/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/06/2022 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
05/02/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
04/25/2022 POS AM Form POS AM - Post-Effective amendments for registration statement:
04/18/2022 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
04/08/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/09/2022 8-K Quarterly results
03/02/2022 4 van Hylckama Vlieg Johan (Chief Scientific Officer) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Paid exercise price by delivering 2,087 restricted stock units @ $1.49, valued at $3.1k
03/02/2022 4 Korn Jerald (COO & General Counsel) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Paid exercise price by delivering 2,046 restricted stock units @ $1.49, valued at $3k
02/09/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/28/2022 8-K Other Events  Interactive Data
01/18/2022 4 van Hylckama Vlieg Johan (Chief Scientific Officer) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 350,000 restricted stock units @ $0
01/18/2022 4 Long Alison S (Chief Medical Officer) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 46,800 restricted stock units @ $0
Granted 125,000 restricted stock units @ $0
01/18/2022 4 Korn Jerald (COO & General Counsel) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 45,240 restricted stock units @ $0
Granted 250,000 restricted stock units @ $0
01/18/2022 4 Duke William E. (CFO) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 44,990 restricted stock units @ $0
Granted 125,000 restricted stock units @ $0
01/18/2022 4 Menichella Daniel L (CEO) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 70,200 restricted stock units @ $0
Granted 250,000 restricted stock units @ $0
12/16/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2021 3 Form 3 - Initial statement of beneficial ownership of securities:
11/01/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/01/2021 8-K Quarterly results
Docs: "Kaleido Biosciences Reports Third Quarter 2021 Financial Results --Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation-- --Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--"
10/05/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Kaleido R&D Day Presentation, furnished herewith",
"Kaleido Biosciences Announces New Clinical and Preclinical Data Supporting Advancement of KB295 to a Phase 2 Clinical Study in Mild-to-Moderate Ulcerative Colitis KB295 reached its primary endpoint demonstrating favorable safety and tolerability profile"
09/03/2021 8-K Other Events  Interactive Data
09/02/2021 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
09/02/2021 4 van Hylckama Vlieg Johan (Chief Scientific Officer) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 40,000 options to buy @ $6.29, valued at $251.6k
09/02/2021 4 Korn Jerald (General Counsel) has filed a Form 4 on Kaleido Biosciences, Inc.
Txns: Granted 100,000 options to buy @ $6.29, valued at $629k
09/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/11/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/11/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy